This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Tirz GLP-2
Dual GIP and GLP-1 Receptor Agonist
/WHAT_IT_IS
Tirzepatide is a novel investigational peptide that acts as a dual agonist of GIP and GLP-1 receptors, enhancing insulin secretion and improving glycemic control while reducing appetite.
/USAGE
Primarily studied in the treatment of Type 2 diabetes and obesity. Research also explores its cardiovascular and metabolic benefits.
/MECHANISM_OF_ACTION
Activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to regulate blood sugar and appetite.
Reported Benefits
- +Improved insulin sensitivity
- +Appetite suppression
- +Significant weight loss
- +Better glycemic control
Reported Side Effects
- −Nausea
- −Vomiting
- −Constipation
- −Fatigue (in early dosing phase)
/STACKED_WITH
/RESEARCH_NOTES
One of the most promising dual agonist peptides in metabolic research. Shows superior outcomes in weight reduction vs. GLP-1 monotherapy.
/REFERENCE
https://cardiab.biomedcentral.com/articles/10.1186/s12933-021-01412-5/RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.